MANKIND - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.0
✅ Positive
The company reported a significant increase in profit (29.6%) and revenue growth (12.9%) during the Q1 period, suggesting healthy operational performance. Furthermore, the sale of the Broadway Hospitality stake generated ₹49 crore, providing a boost to overall financials.
⚠️ Limitation
Despite positive earnings, the stock’s current price remains relatively high compared to its industry average PE ratio of 33.6, indicating potential overvaluation. The recent fall in FII holding and the PEG ratio of 2.22 raise concerns about investor sentiment and future growth prospects.
📉 Company Negative News
Recent news indicates a 5% drop in share price despite rising profits, suggesting investors may be wary of future earnings or broader market conditions.
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical sector is currently experiencing moderate growth driven by increasing healthcare spending and demand for generic drugs, although competition remains intense. Several companies are focusing on expanding their product portfolios and geographical reach.
🧾 Conclusion
Based on the current price of 2,470 ₹, a short-term entry strategy could be considered around 2,380 ₹ - 2,410 ₹, utilizing support levels identified by the DMA 200 (2,350 ₹). A stop-loss order should be placed at approximately 2,300 ₹ to mitigate downside risk. The stock appears to be in a consolidation phase with mixed signals, requiring careful monitoring of volume and momentum shifts.